PLUS1
148.81
-1.00 (-0.67%)
-1.00 (-0.67%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | LLY | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -1.00 | -0.67% | 148.81 | 14:42:28 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 147.37 | 149.66 | 149.26 | 149.81 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 20,497 | 1,525,385 | $ 148.83 | $ 227,018,168 | 3,135,918 | 101.36 - 170.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:42:28 | 1 | $ 148.81 | USD |
Eli Lilly Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 142.33B | 956.47M | 788.89M | $ 22.32B | $ 5.38B | 8.77 | 24.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 4.66M | $ 2.58 | 1.73% | - | - |
Eli Lilly News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/23/2020 | 17:06 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/22/2020 | 09:29 | GlobeNewswire Inc. | Trulicity® (dulaglutide) is now indicated as an adjunct to.. |
| 9/20/2020 | 14:01 | PR Newswire (US) | Verzenio® Significantly Reduced the Risk of Cancer.. |
| 9/18/2020 | 08:38 | Dow Jones News | Eli Lilly: CHMP Recommends Approval of Baricitinib in Atopic.. |
| 9/18/2020 | 07:44 | PR Newswire (US) | CHMP Recommends Approval of Lilly's Baricitinib for the.. |
| 9/17/2020 | 14:21 | Dow Jones News | Lilly, Incyte Trial for Covid-19 Treatment With Baricitinib.. |
| 9/17/2020 | 13:41 | GlobeNewswire Inc. | Baricitinib in Combination with Remdesivir Reduces Time to.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LLY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 150.16 | 154.50 | 147.37 | 152.51 | 5,346,514 | -1.35 | -0.9% |
| 1 Month | 150.49 | 155.50 | 145.715 | 150.35 | 3,793,408 | -1.68 | -1.12% |
| 3 Months | 164.07 | 170.75 | 145.715 | 154.65 | 3,015,452 | -15.26 | -9.3% |
| 6 Months | 122.20 | 170.75 | 117.41 | 151.81 | 3,582,601 | 26.61 | 21.78% |
| 1 Year | 114.36 | 170.75 | 101.36 | 139.37 | 3,686,605 | 34.45 | 30.12% |
| 3 Years | 83.87 | 170.75 | 73.69 | 117.05 | 4,773,490 | 64.94 | 77.43% |
| 5 Years | 86.37 | 170.75 | 64.18 | 103.08 | 4,471,330 | 62.44 | 72.29% |
Eli Lilly Description
| Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. |
